Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2024-03-17 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
赛隆药业集团股份有限公司独立董事提名人声明与承诺（潘传云）
Board/Management Information Classification · 95% confidence The document is a formal statement and commitment regarding the nomination of an independent director candidate for the company's board. It includes detailed declarations about the nominee's qualifications, compliance with regulatory requirements, and independence criteria. There are no financial statements, earnings data, or report summaries. The document is a regulatory announcement related to board management but does not announce a change in board members or senior management itself. It is not a full report, call transcript, or financial release. Given the nature of the content—nomination and compliance statements for an independent director candidate—it fits best under Board/Management Information (MANG), which covers announcements related to board or senior management changes or nominations.
2024-03-17 Chinese
公司章程修正案
Governance Information Classification · 95% confidence The document is a detailed amendment to the company's Articles of Association (公司章程) including governance structure, shareholder meeting procedures, profit distribution policies, and other corporate governance matters. It references compliance with regulatory guidelines and internal company rules. The content focuses on governance rules and policies rather than financial results, audit opinions, or management discussion of financial performance. It is not a report of financial results, audit, or earnings, nor is it a notice of voting results or a proxy solicitation. The document is a governance-related update, specifically about the company's internal rules and governance practices. Therefore, the most appropriate classification is Governance Information (CGR). The document length (8420 characters) and detailed content support this classification with high confidence.
2024-03-17 Chinese
赛隆药业集团股份有限公司独立董事候选人声明与承诺（潘传云）
Board/Management Information Classification · 95% confidence The document is a detailed declaration and commitment statement by an independent director candidate for a company's board. It includes statements of compliance with legal and regulatory requirements, qualifications, and commitments related to the role of an independent director. There are no financial statements, earnings data, or report summaries. The document is not an announcement of a report publication but a formal declaration related to board/management matters. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or appointments in the company's board or senior management.
2024-03-17 Chinese
关于参加最近一次独立董事培训并取得独立董事资格证书的承诺（李公奋）
Regulatory Filings
2024-03-17 Chinese
关于召开2024年第一次临时股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about convening the 2024 first extraordinary general meeting (临时股东大会) of the company 赛隆药业集团股份有限公司. It includes information about the meeting date, voting procedures (including cumulative voting for board and supervisory board members), agenda items such as election of directors and amendments to the company articles, registration details, and proxy forms. The content is focused on informing shareholders about the meeting logistics and agenda, not on reporting financial results or management commentary. This matches the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual or Extraordinary General Meeting. The document is over 5,000 characters and contains substantive meeting details, not just an announcement of a report publication or a regulatory filing. Therefore, the correct classification is AGM Information (AGM-R).
2024-03-17 Chinese
赛隆药业集团股份有限公司独立董事候选人声明与承诺（李公奋）
Board/Management Information Classification · 95% confidence The document is a detailed declaration and commitment statement by an independent director candidate for a company's board. It includes statements about qualifications, compliance with laws and regulations, and commitments related to the role of an independent director. There is no financial data, no report of financial results, no voting results, no management changes, and no other financial or regulatory filings. The document is a formal statement related to board/management information, specifically about a candidate for the board of directors. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is under 5,000 characters and is not an announcement of a report publication or certification, so it is not RPA or RNS.
2024-03-17 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.